IT1164730B - Preparati farmaceutici a base di glucuronidi procedimento per produrli e loro impiego contro tumori - Google Patents
Preparati farmaceutici a base di glucuronidi procedimento per produrli e loro impiego contro tumoriInfo
- Publication number
- IT1164730B IT1164730B IT50529/79A IT5052979A IT1164730B IT 1164730 B IT1164730 B IT 1164730B IT 50529/79 A IT50529/79 A IT 50529/79A IT 5052979 A IT5052979 A IT 5052979A IT 1164730 B IT1164730 B IT 1164730B
- Authority
- IT
- Italy
- Prior art keywords
- aglycone
- beta
- glucuronide
- activity
- radio
- Prior art date
Links
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 title abstract 4
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 title abstract 4
- 239000002253 acid Substances 0.000 title abstract 4
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 title abstract 4
- 229930182480 glucuronide Natural products 0.000 title abstract 3
- 150000008134 glucuronides Chemical class 0.000 title abstract 3
- 231100000433 cytotoxic Toxicity 0.000 title abstract 2
- 230000001472 cytotoxic effect Effects 0.000 title abstract 2
- 230000000694 effects Effects 0.000 abstract 3
- 210000004881 tumor cell Anatomy 0.000 abstract 3
- 241000894006 Bacteria Species 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 238000001514 detection method Methods 0.000 abstract 2
- 230000020477 pH reduction Effects 0.000 abstract 2
- 230000002285 radioactive effect Effects 0.000 abstract 2
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical class OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 abstract 1
- -1 2-phenyl-6-chlorophenyl Chemical group 0.000 abstract 1
- WADQOGCINABPRT-UHFFFAOYSA-N 3-chloro-2-methylphenol Chemical compound CC1=C(O)C=CC=C1Cl WADQOGCINABPRT-UHFFFAOYSA-N 0.000 abstract 1
- KFZXVMNBUMVKLN-UHFFFAOYSA-N 4-chloro-5-methyl-2-propan-2-ylphenol Chemical compound CC(C)C1=CC(Cl)=C(C)C=C1O KFZXVMNBUMVKLN-UHFFFAOYSA-N 0.000 abstract 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 abstract 1
- 241000588724 Escherichia coli Species 0.000 abstract 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 abstract 1
- 102000053187 Glucuronidase Human genes 0.000 abstract 1
- 108010060309 Glucuronidase Proteins 0.000 abstract 1
- GYCMBHHDWRMZGG-UHFFFAOYSA-N Methylacrylonitrile Chemical compound CC(=C)C#N GYCMBHHDWRMZGG-UHFFFAOYSA-N 0.000 abstract 1
- 241000191940 Staphylococcus Species 0.000 abstract 1
- 241000194017 Streptococcus Species 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 229940031956 chlorothymol Drugs 0.000 abstract 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 abstract 1
- 229940097043 glucuronic acid Drugs 0.000 abstract 1
- 238000011065 in-situ storage Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 abstract 1
- 229960001237 podophyllotoxin Drugs 0.000 abstract 1
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 abstract 1
- 230000003439 radiotherapeutic effect Effects 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 210000002700 urine Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/18—Acyclic radicals, substituted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2334/00—O-linked chromogens for determinations of hydrolase enzymes, e.g. glycosidases, phosphatases, esterases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Physiology (AREA)
- General Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/951,269 US4584368A (en) | 1978-10-13 | 1978-10-13 | β-Glucuronidase activity and/or pH-dependent pharmaceuticals and thier methods of production |
| US05/951,270 US4424348A (en) | 1978-10-13 | 1978-10-13 | Methods of manufacture of nitrile-containing glucuronic acid conjugates |
| US06/011,619 US4327074A (en) | 1978-10-13 | 1979-02-12 | Method for diagnosis and selective treatment of infections of bacteria having β-glucuronidase activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IT7950529A0 IT7950529A0 (it) | 1979-10-11 |
| IT1164730B true IT1164730B (it) | 1987-04-15 |
Family
ID=27359461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IT50529/79A IT1164730B (it) | 1978-10-13 | 1979-10-11 | Preparati farmaceutici a base di glucuronidi procedimento per produrli e loro impiego contro tumori |
Country Status (12)
| Country | Link |
|---|---|
| JP (1) | JPS55500837A (OSRAM) |
| AU (1) | AU534068B2 (OSRAM) |
| CA (1) | CA1148086A (OSRAM) |
| CH (1) | CH652724A5 (OSRAM) |
| DE (1) | DE2953223T1 (OSRAM) |
| FR (2) | FR2440374B1 (OSRAM) |
| GB (1) | GB2055044B (OSRAM) |
| IL (1) | IL58352A (OSRAM) |
| IT (1) | IT1164730B (OSRAM) |
| NL (1) | NL7920107A (OSRAM) |
| SE (1) | SE461983B (OSRAM) |
| WO (1) | WO1980000791A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4490523A (en) * | 1981-11-10 | 1984-12-25 | Ely J. Rubin | Mandelonitrile triacetyl glucuronate and process for preparing same |
| AU594855B2 (en) * | 1988-01-15 | 1990-03-15 | Baker Norton Pharmaceuticals, Inc. | Glucuronic acid derivatives of opioid antagonists |
| US5985927A (en) * | 1995-03-30 | 1999-11-16 | Kreutz; Werner | Medicaments for the selective treatment of tumor tissues |
| WO2014138723A2 (en) * | 2013-03-08 | 2014-09-12 | Cognate3 Llc | Physical optimization beverage |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB788855A (en) * | 1953-06-30 | 1958-01-08 | Ernst Theodore Krebs | Improvements in or relating to mandelo-nitrile-glucuronosides and method of making the same |
| US2985664A (en) * | 1957-05-29 | 1961-05-23 | Ernst T Krebs | Hexuronic acid derivatives |
| US3758455A (en) * | 1970-05-14 | 1973-09-11 | Chugai Pharmaceutical Co Ltd | Reof mycophenolic acid glucuronide and the process for the preparation the |
| DE2212014A1 (de) * | 1971-04-21 | 1972-10-26 | Deutsche Akademie der Wissenschaf ten zu Berlin, χ 1199 Berlin | Verfahren zur fermentativen Spaltung von Transportformen von Chemotherapeutika, insbesondere Cancerostatica |
| USRE29465E (en) * | 1972-08-14 | 1977-11-01 | Eli Lilly And Company | Psoriasis treatment with mycophenolic acid |
| US3880995A (en) * | 1973-05-14 | 1975-04-29 | Lilly Co Eli | Treatment of arthritis with mycophenolic acid and derivatives |
| US3959253A (en) * | 1973-07-02 | 1976-05-25 | Merck & Co., Inc. | β-D-glucosyluronic acid derivatives |
| JPS5325534A (en) * | 1976-08-24 | 1978-03-09 | Rikagaku Kenkyusho | Mandelic acid glucosides and their anti-cancerous preparations |
-
1979
- 1979-09-24 AU AU51120/79A patent/AU534068B2/en not_active Ceased
- 1979-09-28 IL IL58352A patent/IL58352A/xx unknown
- 1979-10-02 CH CH4668/80A patent/CH652724A5/de not_active IP Right Cessation
- 1979-10-02 NL NL7920107A patent/NL7920107A/nl unknown
- 1979-10-02 JP JP50180979A patent/JPS55500837A/ja active Pending
- 1979-10-02 DE DE792953223T patent/DE2953223T1/de active Granted
- 1979-10-02 WO PCT/US1979/000809 patent/WO1980000791A1/en not_active Ceased
- 1979-10-02 GB GB8015763A patent/GB2055044B/en not_active Expired
- 1979-10-10 FR FR7925183A patent/FR2440374B1/fr not_active Expired
- 1979-10-11 IT IT50529/79A patent/IT1164730B/it active
- 1979-10-12 CA CA000337483A patent/CA1148086A/en not_active Expired
-
1980
- 1980-04-30 FR FR8009746A patent/FR2449284A1/fr not_active Withdrawn
- 1980-06-12 SE SE8004369A patent/SE461983B/sv not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NL7920107A (nl) | 1980-08-29 |
| CH652724A5 (de) | 1985-11-29 |
| GB2055044B (en) | 1983-04-20 |
| FR2440374A1 (fr) | 1980-05-30 |
| DE2953223C2 (OSRAM) | 1989-05-18 |
| FR2440374B1 (fr) | 1986-03-21 |
| WO1980000791A1 (en) | 1980-05-01 |
| CA1148086A (en) | 1983-06-14 |
| SE461983B (sv) | 1990-04-23 |
| DE2953223T1 (de) | 1980-11-27 |
| AU534068B2 (en) | 1984-01-05 |
| SE8004369L (sv) | 1980-06-12 |
| IL58352A (en) | 1985-11-29 |
| IT7950529A0 (it) | 1979-10-11 |
| GB2055044A (en) | 1981-02-25 |
| JPS55500837A (OSRAM) | 1980-10-23 |
| AU5112079A (en) | 1981-04-16 |
| FR2449284A1 (fr) | 1980-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Eno et al. | Gamma radiation compared with steam and methyl bromide as a soil sterilizing agent | |
| DE68928946D1 (de) | Verfahren zum aufspüren von diagnostischen oder therapeutischen mitteln durch antikörper | |
| Pollock et al. | Isolation and elimination of pleuropneumonia-like organisms from mammalian cell cultures. | |
| IT1164730B (it) | Preparati farmaceutici a base di glucuronidi procedimento per produrli e loro impiego contro tumori | |
| Spencer et al. | In vitro transport of radiolabeled vitamins by the small intestine | |
| Ormerod et al. | Repair of radiation damage in a nucleoprotein by cysteamine | |
| GB857992A (en) | Apparatus for the radio-active radiation treatment of the inner cavities of a body | |
| Keisch et al. | Preliminary report on 10 patients treated with radiotherapy after radical prostatectomy for isolated elevation of serum PSA levels | |
| Preston et al. | Type-specific immunity against intracerebral pertussis infection in mice | |
| BR8300068A (pt) | Processo para o tratamento da acicla em ovelhas ou gado e emprego de gestagenio e th-rh ou seus analogos | |
| ScHEINBERG et al. | Immunization against intracerebral transplantation of a glioma in mice | |
| Kroeger et al. | Inactivation of the influenza virus by low voltage roentgen rays | |
| Mylrea | Passage of antibiotics through the digestive tract of normal and scouring calves and their effect upon the bacterial flora | |
| Barber et al. | Radiosensitivity of salt uptake in plants | |
| Kossakowski et al. | Decontamination effectiveness of ferric ferrocyanide and ammonium-ferric-cyano-ferrate in rats contaminated with radiocaesium | |
| JPS56166124A (en) | Diagnostic injection for malignant tumor | |
| Lawrence et al. | Effect of radiations on microorganisms and certain biological systems: progress report | |
| Anand et al. | A modified technique for the detection of antibiotic synergism | |
| Keen et al. | Malignant disease in the Transvaal. IV. Tumours of the vascular system. V. Neoplasia of the haemopoietic and reticulo-endothelial system. VI. Cancer of the alimentary tract; first statistical report of the Radiation Therapy Department of the Johannesburg Group of Hospitals | |
| KAPLAN | Radium and radon therapy; an evaluation of this form of therapy based upon an experience of 27 years in the treatment of benign and malignant disease in a large municipal general hospital | |
| Mossman et al. | Actinomycin D: Its dual role in radioprotection and radiosensitization to gamma radiation in Tetrahymena | |
| Kim et al. | Brainstem Tumors: Results of 20 Patients Treated with Radiation Therapy | |
| KIM et al. | A clinical observation on hydrocele | |
| Loken et al. | Inactivation of Pepsin by Roentgen Radiation: II. Effect of Different Enzyme Concentrations or Various Organic Compounds | |
| Unak et al. | Anti-cancer drug potential of radioiodinated glucuronide conjugate of {beta}-naphthol |